Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Core Insights - Caribou Biosciences, Inc. announced promising clinical data from the CaMMouflage phase 1 trial for CB-011, an allogeneic CAR-T cell therapy targeting relapsed or refractory multiple myeloma, indicating its potential as a best-in-class treatment option [1][3][5] Company Overview - Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for severe diseases, with a particular emphasis on CAR-T cell therapies [9] Clinical Trial Details - The CaMMouflage phase 1 trial is evaluating CB-011 in adults with relapsed or refractory multiple myeloma who have undergone three or more prior therapies, utilizing a 3+3 dose escalation design [8] - The trial included 48 patients, with a recommended dose for expansion (RDE) set at 450 million CAR-T cells, and the dose expansion phase is expected to begin by the end of 2025 [3][8] Efficacy and Safety Data - In the RDE cohort of 12 BCMA-naïve patients, the overall response rate (ORR) was 92% (11/12), with a complete response (CR) rate of 75% (9/12) and 91% (10/11) achieving minimal residual disease (MRD) negativity [4][3] - The safety profile of CB-011 was manageable, with no cases of graft-versus-host disease or severe immune-related complications reported [2][4] Future Plans - The company plans to share additional data from the dose expansion phase in 2026, following the initiation of this phase by the end of 2025 [1][5]